+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antisense & RNAi Therapeutics Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5204976
  • Report
  • November 2020
  • Region: Global
  • 200 pages
  • The Business Research Company

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Acuitas Therapeutics
  • Calando Pharmaceuticals
  • Gene Signal
  • Ionis Pharmaceuticals
  • OncoGeneX Pharmaceuticals
  • Rxi Pharmaceuticals
Antisense & RNAi Therapeutics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market.

This report focuses on antisense & RNAi therapeutics market which is experiencing strong growth. The report gives a guide to the antisense & RNAi therapeutics market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the antisense & RNAi therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antisense & RNAi Therapeutics market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider antisense & RNAi therapeutics market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The antisense & RNAi therapeutics market section of the report gives context. It compares the antisense & RNAi therapeutics market with other segments of the antisense & RNAi therapeutics market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, antisense & RNAi therapeutics indicators comparison.
Scope

Markets Covered:
1) By Technology: RNA Interference; Antisense RNA
2) By Route of Administration: Pulmonary Delivery; Intravenous Injections; Intra-dermal Injections; Intraperitoneal Injections; Topical Delivery; Other Delivery Methods
3) By Indication: Oncology; Cardiovascular Diseases (CVDs); Respiratory Disorders; Neurological Disorders; Infectious Diseases; Other

Companies Mentioned: Alnylam Pharmaceuticals; Benitec Biopharma Ltd.; Gene Signal; GlaxoSmithKline Plc; Ionis Pharmaceuticals

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acuitas Therapeutics
  • Calando Pharmaceuticals
  • Gene Signal
  • Ionis Pharmaceuticals
  • OncoGeneX Pharmaceuticals
  • Rxi Pharmaceuticals
1. Executive Summary

2. Antisense & RNAi Therapeutics Market Characteristics

3. Antisense & RNAi Therapeutics Market Size And Growth
3.1. Global Antisense & RNAi Therapeutics Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Antisense & RNAi Therapeutics Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Antisense & RNAi Therapeutics Market Segmentation
4.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • RNA Interference
  • Antisense RNA
4.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Pulmonary Delivery
  • Intravenous Injections
  • Intra-dermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Other Delivery Methods
4.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Other
5. Antisense & RNAi Therapeutics Market Regional And Country Analysis
5.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Antisense & RNAi Therapeutics Market
6.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview
6.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Antisense & RNAi Therapeutics Market
7.1. China Antisense & RNAi Therapeutics Market Overview
7.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Antisense & RNAi Therapeutics Market
8.1. India Antisense & RNAi Therapeutics Market Overview
8.2. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Antisense & RNAi Therapeutics Market
9.1. Japan Antisense & RNAi Therapeutics Market Overview
9.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Antisense & RNAi Therapeutics Market
10.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Antisense & RNAi Therapeutics Market
11.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Antisense & RNAi Therapeutics Market
12.1. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Antisense & RNAi Therapeutics Market
13.1. Western Europe Antisense & RNAi Therapeutics Market Overview
13.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Antisense & RNAi Therapeutics Market
14.1. UK Antisense & RNAi Therapeutics Market Overview
14.2. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Antisense & RNAi Therapeutics Market
15.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Antisense & RNAi Therapeutics Market
16.4. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Antisense & RNAi Therapeutics Market
17.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview
17.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Antisense & RNAi Therapeutics Market
18.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Antisense & RNAi Therapeutics Market
19.1. North America Antisense & RNAi Therapeutics Market Overview
19.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Antisense & RNAi Therapeutics Market
20.1. USA Antisense & RNAi Therapeutics Market Overview
20.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Antisense & RNAi Therapeutics Market
21.1. South America Antisense & RNAi Therapeutics Market Overview
21.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Antisense & RNAi Therapeutics Market
22.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Antisense & RNAi Therapeutics Market
23.1. Middle East Antisense & RNAi Therapeutics Market Overview
23.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Antisense & RNAi Therapeutics Market
24.1. Africa Antisense & RNAi Therapeutics Market Overview
24.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles
25.1. Antisense & RNAi Therapeutics Market Competitive Landscape
25.2. Antisense & RNAi Therapeutics Market Company Profiles
25.2.1. Alnylam Pharmaceuticals
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Benitec Biopharma Ltd.
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Gene Signal
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. GlaxoSmithKline Plc
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Ionis Pharmaceuticals
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

27. Antisense & RNAi Therapeutics Market Trends And Strategies

28. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright And Disclaimer


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acuitas Therapeutics
  • Calando Pharmaceuticals
  • Gene Signal
  • Ionis Pharmaceuticals
  • OncoGeneX Pharmaceuticals
  • Rxi Pharmaceuticals
Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd.

The global antisense & RNAi therapeutics market is expected to decline from $1.14 billion in 2019 to $1.11 billion in 2020 at a compound annual growth rate (CAGR) of -2.89%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.44 billion in 2023 at a CAGR of 9.23%.

The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.

North America was the largest region in the antisense & RNAi therapeutics market in 2019. Asia Pacific is expected to be the fastest-growing region in the forecast period.

The antisense & RNAi therapeutics market covered in this report is segmented by technology into RNA interference; antisense RNA. It is also segmented by route of administration into pulmonary delivery; intravenous injections; intra-dermal injections; intraperitoneal injections; topical delivery; other delivery methods and by indication into oncology; cardiovascular diseases (CVDs); respiratory disorders; neurological disorders; infectious diseases; other.

In November 2019, Novartis International AG, a Switzerland-based pharmaceutical company acquired The Medicines Company, a US-based biopharmaceutical company, for $9.7 million. With the acquisition of The Medicines Company, Novartis International AG plans to enter RNA therapeutics by acquiring its last stage RNA interference drug designed for protection against cardiovascular diseases in twice-yearly shorts. The drug has met the primary endpoint in the three phases of clinical trials and is approved for the treatment of cardiovascular diseases in the USA in 2019 and the EU in early 2020. The Medicines Company is a US-based company focused on the development of RNA drug inclisiran that is used in the treatment of renal impairment and cardiovascular diseases.

The high cost of RNA interference-based drugs is expected to act as a major restraint for the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Stringent regulations, long product approval process, high development cost, and a comparably small number of patients are few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics’ market growth in upcoming years.

Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2018, Biogen and Ionis announced a collaboration to develop antisense drug candidates for neurological diseases. This collaboration utilizes Biogen’s expertise in neuroscience research and drug development and Ionis’ knowledge in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. The two companies signed an agreement for 10 years.

The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease is the most common neurodegenerative diseases affecting millions of people globally. In the USA, an estimated 930,000 people are expected to have Parkinson’s disease by the end of 2020. Furthermore, according to the World Health Organization (WHO), infectious diseases are a major concern and dominated the WHO’s list of 2019 health threats ranging from various climate change issues to inadequate healthcare facilities. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.
Note: Product cover images may vary from those shown
  • Alnylam Pharmaceuticals
  • Benitec Biopharma Ltd.
  • Gene Signal
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals
  • Marina Biosciences
  • Quark Pharmaceuticals
  • Sanofi S.A
  • Acuitas Therapeutics
  • Antisense Therapeutics Ltd.
  • Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
  • Bio-Path Holdings Inc.
  • Calando Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Enzon Pharmaceuticals Inc
  • Gradalis
  • iCo Therapeutics
  • miRagen Therapeutics
  • Olix Pharmaceuticals
  • OncoGeneX Pharmaceuticals
  • Lorus Therapeutics (Aptose Biosciences)
  • Regulus Therapeutics
  • Rexahn Pharmaceuticals
  • Rxi Pharmaceuticals
  • Santaris Pharma A/S (Roche)
  • Sarepta Therapeutics
  • Silence Therapeutics Plc
  • Sirnaomics Inc.
  • Tekmira Pharmaceuticals
  • Cenix BioScience
  • Sirnaomics
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll